GoodRx price target raised to $4.75 from $4.25 at BofA

BofA raised the firm’s price target on GoodRx (GDRX) to $4.75 from $4.25 and keeps an Underperform rating on the shares. GoodRx introduced 2025 guidance that was better than the firm expected given the amount of marketplace changes beginning to take place this year, but BofA remains cautious on the growth trajectory in 2025 and beyond, the analyst tells investors.